A Phase 1, Randomzied, Double-blind, Third-party Open Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Intravenous And Multiple Subcutaneous And Intravenous Doses Of Pf-06480605 In Healthy Subjects
Latest Information Update: 25 Oct 2023
At a glance
- Drugs RVT-3101 (Primary) ; RVT-3101 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; First in man
- Sponsors Pfizer; Telavant
- 17 Oct 2023 Protocol of this study has been amended as Sequential has been added in design terms for interventional study model.
- 23 Nov 2019 Results assessing safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of intravenous and subcutaneous PF-06480605 in healthy subjects published in the British Journal of Clinical Pharmacology
- 27 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.